Regulation of synaptic proteasome activity by the dynactin complex
dynactin 复合物对突触蛋白酶体活性的调节
基本信息
- 批准号:7783286
- 负责人:
- 金额:$ 32.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-02-01 至 2015-01-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAlzheimer&aposs DiseaseAmyotrophic Lateral SclerosisAxonal TransportBindingBinding ProteinsBiochemicalBiological AssayCell membraneCellular AssayCellular biologyComplexDataDepositionDevelopmentDiseaseDrosophila genusDynein ATPaseEnhancersEventFamilyFluorescenceFrontotemporal DementiaFunctional disorderGenesGeneticGenetic ScreeningGenetic TechniquesGluesGoalsGolgi ApparatusGrowthGuanosine Triphosphate PhosphohydrolasesHomologous GeneHumanHuman PathologyImageImpairmentIn VitroInvestigationLinkLipid BindingMaintenanceMediatingMediationMembraneModelingMolecularMolecular GeneticsMonomeric GTP-Binding ProteinsMusMutationNerveNerve DegenerationNervous System PhysiologyNervous system structureNeurodegenerative DisordersNeuronsNeurophysiology - biologic functionOnset of illnessParkinson DiseasePathogenesisPathway interactionsPhenocopyProcessProteasome InhibitionProteinsReagentRegulationReporterResolutionRoleSequence AnalysisSignal TransductionStructureSynapsesSystemTertiary Protein StructureVesiclebasedesigndynactinflyhuman diseasein vivointerestmulticatalytic endopeptidase complexmutantnervous system disorderneurodegenerative phenotypeneurological pathologyneurotransmissionnovelnovel strategiesoverexpressionpresynapticprogressive neurodegenerationprotein aggregateprotein complexprotein degradationpublic health relevanceresponserhosynaptic functiontooltrafficking
项目摘要
DESCRIPTION (provided by applicant): Pinpointing the underlying cause of many neurodegenerative diseases has been difficult due to the complexity of neuronal cellular biology and the lack of basic information about impaired mechanisms that contribute to disease. Mutations in the human DCTN1 gene, which encodes a component of the dynactin complex, have been strongly linked to both familial and sporadic cases of amyotrophic lateral sclerosis (ALS). Many of the neurodegenerative phenotypes associated with human disease have been recapitulated in flies and mice harboring dynactin complex mutations demonstrating a conserved pathogenesis in dynactin complex mutants. To clarify the mechanisms that contribute to the pathogenesis of neurodegeneration observed in dynactin complex mutants, especially the degeneration of synaptic contacts, we will use a combination of forward genetic screens and quantitative cellular assays to identify and characterize important modifiers of dynactin complex function at the synapse. We believe that this approach has the potential to identify and describe new genes and pathways required within the nervous system for normal synaptic growth, synapse stabilization, and function. A genetic screen designed to specifically identify genetic modifiers of the Drosophila DCTN1 homolog, glued, within the nervous system has identified the Drosophila homologue of the Arfaptin2 gene, Darfaptin2 (Darf2). We find that Darf2 is expressed in motorneurons and required for normal synaptic growth. The goal of this proposal is to investigate the hypothesis that Darfaptin2 (Darf2) represents a novel component of the dynactin complex required for normal synaptic growth, stabilization, and neurotransmission. Models of Arfaptin2 function include the mediation of cross-talk between Rho-like GTPases and Arf family GTPases during vesicle formation, and the regulation of proteasome activity within neurons. Using standard genetic techniques and synaptic analyses, we will first define the role of Darf2 in the regulation of synaptic growth and synapse stabilization. This will include the biochemical analysis of its association with the dynactin complex in the nervous system (Aim1). We will further investigate the role of Darf2 in the nervous system using a structure-function approach to define protein domains required for normal Darf2 activity. This will include determining the signaling context for Darf2 during synapse growth and stabilization (Aim2). Finally, we are developing reagents and assays to directly investigate the regulation of proteasome function in the nerve terminal by the dynactin complex, Darf2, and during synapse retraction (Aim3). It is expected that these studies will reveal a novel regulatory mechanism during synaptic growth, stabilization, and neurotransmission that will have important implications for the pathogenesis of late onset neurological diseases. PUBLIC HEALTH RELEVANCE: A hallmark of neurodegenerative disease is the early and prominent loss of synaptic contacts observed throughout the nervous system that tightly correlates with the decline in neural function. Recent data has demonstrated the importance synapse degeneration to the onset of disease but mechanisms involved in the maintenance of synaptic contacts remain unclear. We predict that studies aimed at elucidating the molecular mechanism associated with the regulation of synapse maintenance will have broad applications to neurological disease and provide the basis for novel strategies for treatment.
描述(申请人提供):由于神经细胞生物学的复杂性,以及缺乏关于导致疾病的受损机制的基本信息,精确定位许多神经退行性疾病的根本原因一直是困难的。人类DCTN1基因编码动力蛋白复合体的一个组成部分,它的突变与肌萎缩侧索硬化症(ALS)的家族性和散发性病例都有强烈的联系。许多与人类疾病相关的神经退行性表型已经在携带dynactin复合体突变的苍蝇和小鼠身上重现,表明dynactin复合体突变具有保守的发病机制。为了阐明dynactin复合体突变体中观察到的神经退行性变的发病机制,特别是突触接触的变性,我们将结合正向遗传筛选和定量细胞分析来鉴定和表征突触处dynactin复合体功能的重要修饰物。我们相信,这种方法有可能识别和描述神经系统内正常突触生长、突触稳定和功能所需的新基因和新途径。一种旨在专门识别神经系统内果蝇DCTN1同源基因Glued的遗传修饰物的遗传屏幕已经确定了果蝇Arfaptin2基因Darfaptin2(Darf2)的同源基因。我们发现Darf2在运动神经元中表达,是正常突触生长所必需的。这一建议的目的是研究Darfaptin2(Darf2)代表正常突触生长、稳定和神经传递所需的动力蛋白复合体的一种新成分的假设。Arfaptin2的功能模型包括在囊泡形成过程中调节Rho样GTP酶和Arf家族GTP酶之间的串扰,以及调节神经元内的蛋白酶体活性。利用标准的基因技术和突触分析,我们将首先确定Darf2在调节突触生长和突触稳定中的作用。这将包括对其与神经系统中的动力蛋白复合体的联系的生化分析(Aim1)。我们将使用结构-功能方法进一步研究Darf2在神经系统中的作用,以定义正常Darf2活动所需的蛋白质结构域。这将包括确定突触生长和稳定期间Darf2的信号背景(AIM2)。最后,我们正在开发试剂和分析方法,以直接研究动力蛋白复合体Darf2和突触收缩期间(Aim3)对神经末梢蛋白酶体功能的调节。预计这些研究将揭示突触生长、稳定和神经传递过程中的一种新的调节机制,这将对迟发性神经疾病的发病机制具有重要意义。公共卫生相关性:神经退行性疾病的一个特征是在整个神经系统观察到的突触接触的早期和明显的丧失,这与神经功能的下降密切相关。最近的数据表明突触退变在疾病发生中的重要性,但参与维持突触接触的机制尚不清楚。我们预测,旨在阐明与突触维持相关的分子机制的研究将在神经系统疾病中有广泛的应用,并为新的治疗策略提供基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Benjamin Arthur Eaton其他文献
Benjamin Arthur Eaton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Benjamin Arthur Eaton', 18)}}的其他基金
Cellular Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
化疗引起的周围神经病变的细胞机制
- 批准号:
8866622 - 财政年份:2015
- 资助金额:
$ 32.48万 - 项目类别:
Regulation of synaptic proteasome activity by the dynactin complex
dynactin 复合物对突触蛋白酶体活性的调节
- 批准号:
8016005 - 财政年份:2010
- 资助金额:
$ 32.48万 - 项目类别:
Regulation of synaptic proteasome activity by the dynactin complex
dynactin 复合物对突触蛋白酶体活性的调节
- 批准号:
8420454 - 财政年份:2010
- 资助金额:
$ 32.48万 - 项目类别:
Regulation of synaptic proteasome activity by the dynactin complex
dynactin 复合物对突触蛋白酶体活性的调节
- 批准号:
8608605 - 财政年份:2010
- 资助金额:
$ 32.48万 - 项目类别:
Regulation of synaptic proteasome activity by the dynactin complex
dynactin 复合物对突触蛋白酶体活性的调节
- 批准号:
8217143 - 财政年份:2010
- 资助金额:
$ 32.48万 - 项目类别:
Characterization of Presynaptic Protein Nerve wracked
突触前蛋白神经损伤的表征
- 批准号:
6529744 - 财政年份:2001
- 资助金额:
$ 32.48万 - 项目类别:
Characterization of Presynaptic Protein Nerve wracked
突触前蛋白神经损伤的表征
- 批准号:
6616700 - 财政年份:2001
- 资助金额:
$ 32.48万 - 项目类别:
Characterization of Presynaptic Protein Nerve wracked
突触前蛋白神经损伤的表征
- 批准号:
6405037 - 财政年份:2001
- 资助金额:
$ 32.48万 - 项目类别: